About Low affinity immunoglobulin epsilon Fc receptor
Low affinity immunoglobulin epsilon Fc receptor (FCER2) is a protein
from Homo sapiens identified by UniProt accession
P06734, 321 residues long.
MolForge cross-references it against 0 known binders and
419 disease associations.
Target properties
| Protein name | Low affinity immunoglobulin epsilon Fc receptor |
| UniProt accession | P06734 |
| Gene | FCER2 |
| Organism | Homo sapiens |
| Length | 321 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (419)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.34
- low affinity immunoglobulin epsilon Fc receptor measurement · score 0.26
- thyroid gland adenocarcinoma · score 0.23
- cerebrospinal fluid biomarker measurement · score 0.23
- breast adenocarcinoma · score 0.23
- glioblastoma multiforme · score 0.21
- neutrophil count · score 0.19
- monocyte percentage of leukocytes · score 0.19
- head and neck squamous cell carcinoma · score 0.19
- gastric adenocarcinoma · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P06734-F1 | alphafold | PREDICTED | 86.42 | — |
Amino-acid sequence (321 residues)
MEEGQYSEIE ELPRRRCCRR GTQIVLLGLV TAALWAGLLT LLLLWHWDTT QSLKQLEERA ARNVSQVSKN LESHHGDQMA QKSQSTQISQ ELEELRAEQQ RLKSQDLELS WNLNGLQADL SSFKSQELNE RNEASDLLER LREEVTKLRM ELQVSSGFVC NTCPEKWINF QRKCYYFGKG TKQWVHARYA CDDMEGQLVS IHSPEEQDFL TKHASHTGSW IGLRNLDLKG EFIWVDGSHV DYSNWAPGEP TSRSQGEDCV MMRGSGRWND AFCDRKLGAW VCDRLATCTP PASEGSAESM GPDSRPDPDG RLPTPSAPLH S
Explore Low affinity immunoglobulin epsilon Fc receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets